The Senate has confirmed Scott Gottlieb, MD, for the position of FDA Commissioner. Gottlieb faced some criticism from Democrats for his close ties to the pharmaceutical industry, but he promised to recuse himself from any FDA decisions relating to some 20 companies and institutions for 1 year.
The Senate has confirmed Scott Gottlieb, MD, for the position of FDA Commissioner by a vote of 57-42. Gottlieb faced some criticism from Democrats for his close ties to the pharmaceutical industry, but he promised to recuse himself from any FDA decisions relating to some 20 companies and institutions for 1 year.
Gottlieb succeeds Robert Califf, MD, who held the position for less than 1 year after being appointed by former President Barack Obama. Califf and his predecessor, Margaret A. Hamburg, MD, both came out in support for Gottlieb. Andy Slavitt, the former acting CMS administrator and another Obama appointee, had also approved of Gottlieb's nomination when the announcement was made in March.
Through his role at the FDA, Gottlieb will be expected to loosen regulatory restrictions to speed up the approval process. Ted Okon, executive director of the Community Oncology Alliance, said in an interview that Gottlieb is also a proponent of incrasing drug price transparency and revamping the drug rebate system.
Gottlieb has previous experience working for the agency. From 2005 to 2007 he was deputy commissioner for medical and scientific affairs.
The California Life Sciences Association (CSLA) applauded the confirmation and noted his track record for protecting public health and promoting innovation.
"With his experience in regulatory matters, and understanding of agency and industry needs, we are confident Dr Gottlieb will be an exemplary leader for the FDA," Sara Radcliffe, president and CEO of CLSA, said in a statement. "We look forward to working with him and his team at the FDA to meet our shared goals."
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More